Wockhardt Limited — Investor Meet, 11-06-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Wockhardt reported FY25 revenue of INR3,033 Cr with EBITDA up 67% YoY at INR418 Cr, boosting margin by 500 bps to 14%. Net debt dropped sharply to INR64 Cr. Novel antibiotics now contribute 18% of sales, led by ZAYNICH (global Phase 3 success, India approval and US launch expected) and Miqnaf (launched in India). The company is expanding its diabetes biosimilar capacity, targeting a doubling of revenues in 3 years. Management highlighted strong execution, cost control, and strategic US commercialization options. Investor sentiment is confident on growth and innovation.